Haoxi Health Technology Limited (HAO) Key Metrics
HAO valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $772,525
- Enterprise value
- −$4.0M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.0
- Price / book
- 0.1
- EV / EBITDA
- 13.5
- Dividend yield
- —
- Beta
- −1.08
HAO key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHAO valuation Price multiples at each fiscal year-end price.
HAO returns How much profit the business earns on the capital it uses.
HAO per-share figures Results divided by the shares outstanding at year-end.
HAO financial health Debt, liquidity and how easily interest is covered.
HAO efficiency & capital use Working capital cycle and where the cash goes.
HAO valuation history
HAO returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HAO debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HAO price vs earnings per share
HAO key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $328.3M | $5.88B | — | — | — | — |
| Enterprise value | $321.7M | $5.87B | — | — | — | — |
| P/E ratio | 84.7 | — | — | — | — | — |
| Price / sales | 10.0 | 121.1 | — | — | — | — |
| Price / book | 18.9 | 521.2 | — | — | — | — |
| EV / sales | 9.8 | 121.0 | — | — | — | — |
| EV / EBITDA | 70.5 | — | — | — | — | — |
| Earnings yield | 1.2% | 0.0% | — | — | — | — |
| Free cash flow yield | −1.0% | −0.0% | — | — | — | — |
| Share price at fiscal year-end | $2,739.20 | $9,600.00 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $273.71 | $79.28 | — | $51.12 | $32.31 | $25.70 |
| Earnings per share | $32.35 | $2.11 | — | $1.76 | $0.49 | $0.61 |
| Operating cash flow per share | −$28.02 | −$1.22 | — | −$1.58 | −$1.35 | $5.30 |
| Free cash flow per share | −$28.02 | −$1.31 | — | −$1.66 | −$1.37 | $5.29 |
| Cash per share | $71.91 | $10.88 | — | $2.18 | $0.59 | $0.11 |
| Book value per share | $144.98 | $18.42 | — | $2.84 | −$2.93 | −$3.86 |
| Tangible book value per share | $129.94 | $18.42 | — | $2.84 | −$2.93 | −$3.86 |
| Capex per share | $0.00 | $0.09 | — | $0.08 | $0.02 | $0.01 |
| Debt per share | $16.64 | $1.96 | — | $1.54 | $1.01 | $0.67 |
| Shares outstanding | 120K | 612K | — | 552K | 500K | 500K |
| Change in shares outstanding | −80.4% | — | — | +10.5% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | 27.1% | 11.5% | 20.1% | — | — | — |
| Return on invested capital (ROIC) | −22.6% | 23.7% | 88.7% | — | — | — |
| Return on assets (ROA) | 20.9% | 8.3% | 12.9% | 38.7% | 14.6% | 10.8% |
| Return on tangible assets | 19.6% | 8.3% | 8.3% | 21.7% | 45.0% | 10.8% |
| Free cash flow margin | −10.2% | −1.7% | −1.7% | −3.3% | −4.2% | 20.6% |
| Income quality (OCF / net income) | −0.87 | −0.58 | −0.58 | −0.90 | −2.76 | 8.71 |
| Financial health | ||||||
| Total debt | $2.0M | $1.2M | $368,043 | $850,060 | $505,399 | $335,029 |
| Cash & short-term investments | $8.6M | $6.7M | $6.7M | $1.2M | $293,511 | $55,886 |
| Net debt | −$6.6M | −$5.5M | −$6.3M | −$353,143 | $211,888 | $279,143 |
| Debt / equity | 0.11 | 0.11 | 0.03 | 0.54 | — | — |
| Debt / assets | 0.09 | 0.08 | 0.02 | 0.19 | 0.93 | 0.12 |
| Net debt / EBITDA | −1.45 | −3.05 | −2.29 | −0.29 | 0.78 | 0.84 |
| Current ratio | 5.05 | 3.98 | 3.98 | 1.43 | 0.22 | 0.56 |
| Quick ratio | 5.05 | 2.64 | 3.98 | 0.49 | 0.21 | 0.46 |
| Interest coverage | -43.5 | 41.7 | 66.8 | 57.2 | 27.0 | 62.7 |
| Working capital | $15.7M | $11.5M | $11.5M | $1.1M | −$1.6M | −$2.0M |
| Invested capital | $10.8M | $5.8M | $5.0M | $1.2M | −$1.3M | −$1.7M |
| Tangible asset value | $15.6M | $11.3M | $11.3M | $1.6M | −$1.5M | −$1.9M |
| Net current asset value | $15.4M | $11.1M | $11.1M | $776,373 | −$1.6M | −$2.1M |
| Graham number | $324.83 | $29.57 | — | $10.59 | — | — |
| Graham net-net per share | $69.79 | $12.53 | — | −$0.80 | −$3.39 | −$5.95 |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 0.1% | 0.1% | 0.2% | 0.1% | 0.0% |
| Capex / operating cash flow | — | — | — | — | — | 0.1% |
| Capex / depreciation | 0.00 | 5.24 | 5.24 | 5.42 | 3.93 | 7.94 |
| R&D / revenue | 0.2% | 0.2% | 0.2% | 0.2% | 0.6% | 0.5% |
| SG&A / revenue | 8.7% | 2.0% | 2.0% | 2.9% | 1.7% | 1.7% |
| Efficiency | ||||||
| Days sales outstanding | 49.2 | 14.2 | 1.1 | 0.5 | 22.3 | 56.0 |
| Days of inventory on hand | — | 41.3 | — | 17.0 | 5.9 | 14.1 |
| Days payables outstanding | 4.6 | 5.2 | 2.7 | 9.1 | 49.4 | 87.2 |
| Cash conversion cycle (days) | 44.5 | 50.3 | -1.6 | 8.4 | -21.2 | -17.1 |
| Receivables turnover | 7.43 | 25.70 | 331.23 | 804.96 | 16.36 | 6.52 |
| Payables turnover | 78.95 | 70.02 | 134.41 | 40.29 | 7.39 | 4.19 |
| Inventory turnover | — | 8.85 | — | 21.49 | 61.73 | 25.97 |
| Asset turnover | 1.77 | 3.13 | 4.86 | 11.28 | 9.63 | 4.57 |
| Average receivables | $4.4M | $1.9M | $146,484 | $35,069 | $987,720 | $2.0M |
| Average payables | $403,780 | $653,694 | $340,519 | $649,477 | $2.1M | $2.9M |
| Average inventory | — | $5.2M | — | $1.2M | $251,245 | $471,458 |
| Intangibles / total assets | 8.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from HAO's annual financial statements (latest annual report filed October 20, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HAO valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Haoxi Health Technology traded at 84.7 times earnings. Haoxi Health Technology earned a return on equity of 27.1% and a return on invested capital of −22.6% in fiscal 2025. It ended the year with $2.0 million of debt and $8.6 million in cash and short-term investments, a net cash position of $6.6 million. The share count fell 76.0% from 500K to 120K over 5 years.
See the HAO income statement, the HAO chart for price history, or the HAO stock overview for the latest quote and news.
HAO key metrics FAQ
What is Haoxi Health Technology's P/E ratio?
Haoxi Health Technology traded at 84.7 times earnings at the end of fiscal 2025.
What is Haoxi Health Technology's EV/EBITDA?
Haoxi Health Technology's enterprise value was 70.5 times EBITDA at the end of fiscal 2025 (enterprise value $321.7 million, EBITDA $4.6 million); the current EV/EBITDA is 13.5.
What is Haoxi Health Technology's return on equity?
Haoxi Health Technology's return on equity (ROE) was 27.1% in fiscal 2025: net income of $3.9 million on average shareholders' equity of $14.3 million.
What is Haoxi Health Technology's ROIC?
Haoxi Health Technology's return on invested capital was −22.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Haoxi Health Technology have?
Haoxi Health Technology had total debt of $2.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.11 and more cash than debt.
What is Haoxi Health Technology's free cash flow yield?
Haoxi Health Technology generated -$3.4 million of free cash flow in fiscal 2025, a free cash flow yield of −1.0% on its market value at year-end ($328.3 million).
What is Haoxi Health Technology's current ratio?
Haoxi Health Technology's current ratio was 5.05 at the end of fiscal 2025: current assets were 5.05 times current liabilities.